Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients .- AstraZeneca

Written by | 7 Jun 2020

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe COVID-19… read more.

RECOVERY trial shows no benefit from hydroxycholoroquine as treatmant for COVID-19.- Novartis

Written by | 7 Jun 2020

In March 2020 RECOVERY was established as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine The trial has proceeded at unprecedented… read more.

Inovio and IVI partner with Seoul National University Hospital to start phase 1/II clinical rial of Inovio’s COVID-19 DNA vaccine (INO-4800) in South Korea.

Written by | 6 Jun 2020

Inovio , the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to start a Phase 1/II clinical trial of INOVIO’s COVID-19 vaccine INO 4800… read more.

Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response.

Written by | 6 Jun 2020

Roche announcedy that the FDA has issued an Emergency Use Authorisation (EUA) for the Elecsys IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and… read more.

Hydroxychloroquine does not offer COVID-19 protection after exposure according to University of Minnesota study.

Written by | 5 Jun 2020

A University of Minnesota trial with results published in the New England Journal of Medicine, goes the furthest in answering the question of whether a decades-old, repurposed hydroxychloroquine… read more.

Recent publication of two papers concerning oral Feraccru/Accrufer treatment for iron deficiency.- Shield Therapeutics

Written by | 4 Jun 2020

Shield Therapeutics plc with its lead product Feraccru/Accrufer (ferric maltol), notes the recent publication of two papers concerning Feraccru/Accrufer.ORal IrON supplementation with ferric maltol in patients with Pulmonary… read more.

Recent publication of two papers concerning oral Feraccru/Accrufer treatment for iron deficiency.- Shield Therapeutics

Written by | 4 Jun 2020

Shield Therapeutics plc with its lead product Feraccru/Accrufer (ferric maltol), notes the recent publication of two papers concerning Feraccru/Accrufer.ORal IrON supplementation with ferric maltol in patients with Pulmonary… read more.

Gilead announces results from phase III trial of remdesivir in patients with moderate COVID-19.- Gilead Sciences.

Written by | 2 Jun 2020

Gilead Sciences, Inc. announced topline results from the Phase iII SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label study evaluated 5-day and 10-day courses of… read more.

Genentech/Roche + Gilead Sciences initiate Phase III trial of Actemra + remdesivir in hospitalized patients with severe COVID-19 pneumonia.

Written by | 29 May 2020

Genentech, a member of the Roche Group announced the initiation of a global Phase III, randomized, double-blind, multicenter study (REMDACTA) to evaluate the safety and efficacy of Actemra… read more.

Remdesivir granted early access in the UK by MHRA for COVID-19 treatment.- Gilead Sciences

Written by | 29 May 2020

Remdesivir has been granted a special early access status in the UK, which will allow patients hospitalized with COVID-19 to receive the antiviral treatment.The public assessment report issued… read more.

Vitamin D and Covid-19

Written by | 27 May 2020

Peter Mas-Mollinedo, CEO of ICR Ltd, joins Professor Rose Anne Kenny to discuss why vitamin D is so important to our immune system, why so many people are… read more.

WHO pausing the hydroxycholoroquine arm of its global COVID-19 drug trials.

Written by | 27 May 2020

The World Health Organization (WHO) is pausing the hydroxycholoroquine arm of its global COVID-19 drug trials after a review found the malaria therapy was associated with raised death… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.